Reportlinker Adds Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, April 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Juvenile Rheumatoid Arthritis Therapeutics market. The report identifies the key trends shaping and driving the global Juvenile Rheumatoid Arthritis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Juvenile Rheumatoid Arthritis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Juvenile Rheumatoid Arthritis Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Juvenile Rheumatoid Arthritis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Juvenile Rheumatoid Arthritis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Juvenile Rheumatoid Arthritis Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Juvenile Rheumatoid Arthritis Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Juvenile Rheumatoid Arthritis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Juvenile Rheumatoid Arthritis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Juvenile Rheumatoid Arthritis Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 JRA Therapeutics: Introduction 6
2.1 Disease Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Signs and Symptoms 7
2.4 Epidemiology 8
2.5 Diagnosis 8
2.6 Treatment and Management Pattern 10
2.7 GlobalData Pipeline Report Guidance 11
3 JRA Therapeutics Market: Market Characterization 12
3.1 Global, Market Size (2005-2010) 12
3.2 Global, Market Forecast (2010-2017) 13
3.3 The US Market Size (2005-2010) 14
3.4 The US Market Forecast (2010-2017) 15
3.5 France Market Size (2005-2010) 16
3.6 France Market Forecast (2010-2017) 17
3.7 Germany Market Size (2005-2010) 18
3.8 Germany Market Forecast (2010-2017) 19
3.9 Italy Market Size (2005-2010) 20
3.10 Italy Market Forecast (2010-2017) 21
3.11 Spain Market Size (2005-2010) 22
3.12 Spain Market Forecast (2010-2017) 23
3.13 The UK Market Size (2005-2010) 24
3.14 The UK Market Forecast (2010-2017) 25
3.15 Japan Market Size (2005-2010) 26
3.16 Japan Market Forecast (2010-2017) 27
3.17 Drivers and Barriers for the JRA Therapeutics Market 28
3.17.1 Drivers for the JRA Therapeutics Market 28
3.17.2 Barriers for the JRA Therapeutics Market 29
3.18 Opportunity and Unmet Need 29
3.19 Key Takeaway 31
4 JRA Therapeutics: Competitive Assessment 32
4.1 Overview 32
4.2 Strategic Competitor Assessment 32
4.3 Product Profile for the Major Marketed Products in the JRA Therapeutics Market 33
4.3.1 NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) 33
4.3.2 Steroids 34
4.3.3 Disease-Modifying Anti-Rheumatic Drugs (DMARDs) 34
4.3.4 Enbrel (etanercept) 35
4.3.5 Humira (adalimumab) 36
4.3.6 Orencia (abatacept) 37
4.4 Key Takeaway 38
5 JRA Therapeutics: Pipeline Assessment 39
5.1 Overview 39
5.2 Strategic Pipeline Assessment 39
5.3 JRA Therapeutics – Pipeline Analysis by Phase of Development 40
5.3.1 JRA Therapeutics – Filed and Phase III Clinical Pipeline 40
5.3.2 JRA Therapeutics Market – Phase II Clinical Pipeline 40
5.3.3 JRA Therapeutics Market – Phase I and Pre-clinical Pipeline 40
5.4 JRA Therapeutics – Pipeline by Mechanism of Action 41
5.5 Technology Trends Analytical Framework 42
5.6 JRA Therapeutics – Most Promising Drugs Under Clinical Development 43
5.7 Most Promising Drug Profiles 44
5.7.1 Actemra (tocilizumab) 44
5.7.2 Ilaris (Canakinumab, ACZ885) 45
5.8 Key Takeaway 45
6 JRA Therapeutics: Clinical Trials Mapping 46
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan) 46
6.2 Clinical Trials by Phase of Clinical Development 47
6.3 Clinical Trials by Trial Status 48
6.4 Clinical Trials by Sponsors 49
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials 50
7 JRA Therapeutics: Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Future Market Competition Scenario 52
8 JRA Therapeutics: Future Players 53
8.1 Introduction 53
8.2 Company Profiles 54
8.2.1 Novartis AG 54
8.3 Hoffmann-La Roche 59
8.3.2 Centocor Ortho Biotech Inc. 61
8.3.3 Italfarmaco S.p.A. 62
8.4 Details of Other Companies in the Pipeline 64
8.5 Key Takeaway 64
9 JRA Therapeutics: Licensing and Partnership Deals 65
10 JRA Therapeutics: Appendix 66
10.1 Definition 66
10.2 Acronyms 66
10.3 Research Methodology 68
10.3.1 Coverage 68
10.3.2 Secondary Research 68
10.3.3 Forecasting 68
10.3.4 Primary Research 71
10.3.5 Expert Panel Validation 71
10.4 Contact Us 71
10.5 Disclaimer 71
10.6 Bibliography 72
1.1 List of Tables
Table 1: ILAR Classification, Inclusion and Exclusion Criteria for JRA, 2011 6
Table 2: Differential Diagnosis of Juvenile Idiopathic Arthritis in Children 8
Table 3: JRA Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Table 4: JRA Therapeutics Market, Global, Market Forecast ($m), 2010–2017 13
Table 5: JRA Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Table 6: JRA Therapeutics Market, The US, Market Forecast ($m), 2010–2017 15
Table 7: JRA Therapeutics Market, France, Revenue ($m), 2005–2010 16
Table 8: JRA Therapeutics Market, France, Market Forecast ($m), 2010–2017 17
Table 9: JRA Therapeutics Market, Germany, Revenue ($m), 2005–2010 18
Table 10: JRA Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 19
Table 11: JRA Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Table 12: JRA Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 21
Table 13: JRA Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Table 14: JRA Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 23
Table 15: JRA Therapeutics Market, The UK, Revenue ($m), 2005–2010 24
Table 16: JRA Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 25
Table 17: JRA Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Table 18: JRA Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 27
Table 19: JRA Therapeutics, Filed and Phase III, Pipeline, 2011 40
Table 20: JRA Therapeutics, Phase II, Pipeline, 2011 40
Table 21: JRA Therapeutics, Pre-clinical Pipeline, 2011 40
Table 22: JRA Therapeutics, Global, Most Promising Drugs Under Clinical Development, 2011 43
Table 23: JRA Therapeutics, Global, Clinical Trials, 2011 46
Table 24: JRA Therapeutics, Global, Clinical Trials by Phase, 2011 47
Table 25: JRA Therapeutics, Global, Clinical Trials by Status of Development, 2011 48
Table 26: JRA Therapeutics, Global, Prominent Sponsors, 2011 49
Table 27: JRA Therapeutics, Global, Top Ten Companies by Phase by Clinical Trials, 2011 50
Table 28: Novartis Deals, Alliances and Partnerships, 2009-2010 56
Table 29: Novartis AG – JRA Pipeline Products, 2011 58
Table 30: Hoffmann-La Roche Inc. – Deals, Alliances and Partnerships, 2011 61
Table 31: Hoffmann-La Roche Inc – JRA Pipeline Products, 2011 61
Table 32: Centocor Ortho Biotech Inc. – Deals, Alliances and Partnerships, 2011 62
Table 33: Centocor Ortho Biotech Inc. – JRA Pipeline Products, 2011 62
Table 34: Italfarmaco S.p.A. – Deals, Alliances and Partnerships, 2011 63
Table 35: Italfarmaco S.p.A. – JRA Pipeline Products, 2011 63
Table 36: Description of Other Companies in the Pipeline, 2011 64
Table 37: JRA Therapeutics – Licensing and Partnership Deals, 2011 65
1.2 List of Figures
Figure 1: JRA Therapeutics, Etiology and Pathophysiology, 2011 7
Figure 2: JRA Therapeutics Market, Global, Revenue ($m), 2005–2010 12
Figure 3: JRA Therapeutics Market, Global, Market Forecast ($m), 2010–2017 13
Figure 4: JRA Therapeutics Market, The US, Revenue ($m), 2005–2010 14
Figure 5: JRA Therapeutics Market, The US, Market Forecast ($m), 2010–2017 15
Figure 6: JRA Therapeutics Market, France, Revenue ($m), 2005–2010 16
Figure 7: JRA Therapeutics Market, France, Market Forecast ($m), 2010–2017 17
Figure 8: JRA Therapeutics Market, Germany, Revenue ($m), 2005–2010 18
Figure 9: JRA Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 19
Figure 10: JRA Therapeutics Market, Italy, Revenue ($m), 2005–2010 20
Figure 11: JRA Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 21
Figure 12: JRA Therapeutics Market, Spain, Revenue ($m), 2005–2010 22
Figure 13: JRA Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 23
Figure 14: JRA Therapeutics Market, The UK, Revenue ($m), 2005–2010 24
Figure 15: JRA Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 25
Figure 16: JRA Therapeutics Market, Japan, Revenue ($m), 2005–2010 26
Figure 17: JRA Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 27
Figure 18: Opportunity and Unmet Need in the JRA Therapeutics, 2011 30
Figure 19: Strategic Competitor Assessment of the Marketed Products in JRA, 2011 33
Figure 20: JRA Therapeutics – Clinical Pipeline by Mechanism of Action, 2011 41
Figure 21: JRA Therapeutics – Clinical Pipeline by Phase of Development, 2011 41
Figure 22: Technology Trends Analytics Framework, 2011 42
Figure 23: Technology Trends Analytics Framework – Description, 2011 42
Figure 24: JRA Therapeutics, Global, Clinical Trials by Country, 2011 46
Figure 25: JRA Therapeutics, Global, Clinical Trials by Phase, 2011 47
Figure 26: JRA Therapeutics, Global, Clinical Trials by Status of Development, 2011 48
Figure 27: JRA Therapeutics, Global, Overall Sponsors, 2011 49
Figure 28: JRA Therapeutics, Global, Prominent Sponsors, 2011 49
Figure 29: JRA Therapeutics, Global, Top Ten Companies by Phase, 2011 50
Figure 30: JRA Therapeutics, Drivers and Restraints, 2011 51
Figure 31: Implications for Future Market Competition in the JRA Therapeutics, 2011 52
Figure 32: JRA Therapeutics, Clinical Pipeline by Company, 2011 53
Figure 33: GlobalData Market Forecasting Model 70Novartis AG
Hoffmann-La Roche
Centocor Ortho Biotech Inc.
Italfarmaco S.p.A.
To order this report:
: Juvenile Rheumatoid Arthritis (JRA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Contact:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article